Iovance Biotherapeutics (IOVA) Deferred Taxes (2023 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Deferred Taxes of -$665000.0 for Q1 2026, up 63.82% year-over-year from -$405934.9 in Q1 2025, and down 461.41% quarter-over-quarter from $184000.0 in Q4 2025.
Powered by 
Analysis
Iovance Biotherapeutics (IOVA) Deferred Taxes (2023 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Deferred Taxes for 4 consecutive years, with -$665000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Deferred Taxes rose 63.82% year-over-year to -$665000.0; the TTM figure through Mar 2026 stood at -$898000.0 (up 72.44% YoY), while the FY2025 annual figure was -$2.1 million, up 26.77% from the prior year.
- Deferred Taxes slipped to -$665000.0 in Q1 2026 per IOVA's latest filing, from $184000.0 in the prior quarter.
- Across five years, Deferred Taxes topped out at $2.0 million in Q2 2025 and bottomed at -$2.4 million in Q3 2025.
- Historically, Deferred Taxes has averaged -$753583.3 across 4 years, with a median of -$1.3 million in 2023.
- Annual changes were most pronounced in 2024 — Deferred Taxes tumbled 205.66% — and 2025, when it soared 236.35%.
- Iovance Biotherapeutics' Deferred Taxes stood at -$1.8 million in 2023, then surged by 188.63% to $1.6 million in 2024, then slumped by 88.2% to $184000.0 in 2025, then sank by 461.41% to -$665000.0 in 2026.
- Business Quant data shows IOVA's Deferred Taxes at -$665000.0 in Q1 2026, $184000.0 in Q4 2025, and -$2.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.66 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Iovance Biotherapeutics | 3.95 Bn | 3.66 Bn | 55.72 Mn | -1.37 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.37 Mn |
| Mar 31, 2026 | -665,000.00 |
| Dec 31, 2025 | 184,000.00 |
| Sep 30, 2025 | -2.41 Mn |
| Jun 30, 2025 | 1.99 Mn |
| Mar 31, 2025 | -1.84 Mn |
| Dec 31, 2024 | 1.56 Mn |
| Sep 30, 2024 | -1.52 Mn |
| Jun 30, 2024 | -1.46 Mn |
| Mar 31, 2024 | -1.41 Mn |
| Dec 31, 2023 | -1.76 Mn |
| Sep 30, 2023 | -1.24 Mn |
| Jun 30, 2023 | -477,000.00 |